Analysis of the clinical value of O-RADS classification combined with hematological indexes in the diagnosis of benign and malignant tumors of ovary-adnexa

Background: This study aimed to analyze the clinical value of the Ovarian-Adnexal Reporting and Data System (O-RADS) classification combined with hematological indices for the diagnosis of benign and malignant ovarian-adnexa. Methods: A retrospective analysis of 153 cases of ovarian adnexal masses was performed. All patients underwent O-RADS classification, and hematological indexes were measured upon admission, including neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), fibrinogen (FIB), carbohydrate antigen 125 (CA125), carbohydrate antigen 199 (CA199) and human epididymis protein 4 (HE4). Results: The diagnostic results of O-RADS classification were consistent with the pathological findings in 134 cases, while 19 cases showed discrepancies, yielding an accuracy rate of 87.58%, demonstrating good agreement (Kappa = 0.713, p < 0.001). Compared with the benign group, patients in the malignant group exhibited a significantly higher proportion of tumors >5 cm in size (54.81%), as well as elevated neutrophil count, NLR, FIB, CRP, CA125, HE4 and CA199 levels (p < 0.05). Lymphocyte counts were significantly lower in the malignant group (p < 0.05). Multivariate analysis identified NLR, FIB, CRP, CA125 and HE4 as independent risk factors for ovarian-adnexal tumors (p < 0.05). The area under the curve (AUC) values for diagnosing ovarian-adnexal malignancy were as follows: NLR (0.813), FIB (0.788), CRP (0.780), CA125 (0.816), HE4 (0.771) and CA199 (0.604). The combined assessment of hematological indexes yielded an AUC of 0.844. Notably, the combination of O-RADS classification combined with hematological indexes achieved the highest diagnostic performance, with an AUC of 0.955, significantly higher than that of O-RADS or and hematological indexes alone (p < 0.05). Conclusions: Combining O-RADS classification with hematological indexes significantly enhances the diagnostic accuracy for distinguishing benign from malignant ovarian-adnexal masses. This integrated approach facilitates earlier detection and holds significant potential for clinical application in routine screening and diagnosis.

Ovarian-adnexal reporting and data system; Hematological indicators; Ovarian tumors; Malignancy; Diagnostic accuracy

[1] Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Annals of Oncology. 2023; 34: 681–692.

[2] DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim B, Oaknin A, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. Journal of Clinical Oncology. 2023; 41: 609–617.

[3] Lycke M, Ulfenborg B, Malchau Lauesgaard J, Kristjansdottir B, Sundfeldt K. Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics. Clinical Chemistry and Laboratory Medicine. 2021; 59: 1954–1962.

[4] Cartmel B, Li F, Zhou Y, Gottlieb L, Lu L, Mszar R, et al. Randomized trial of exercise on cancer-related blood biomarkers and survival in women with ovarian cancer. Cancer Medicine. 2023; 12: 15492–15503.

[5] Rosario SR, Long MD, Chilakapati S, Gomez EC, Battaglia S, Singh PK, et al. Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer. Nature communications. 2024; 15: 10609.

[6] Bizzarri N, D’Indinosante M, Marchetti C, Tudisco R, Turchiano F, Scambia G, et al. The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer. International Journal of Clinical Oncology. 2023; 28: 314–320.

[7] Wu J, Zhang Y, Liu G, Ge L. New use of preoperative fibrinogen in ovarian cancer management. Translational Cancer Research. 2023; 12: 3105–3112.

[8] Vara J, Manzour N, Chacón E, López-Picazo A, Linares M, Pascual M, et al. Ovarian adnexal reporting data system (O-RADS) for classifying adnexal masses: a systematic review and meta-analysis. Cancers. 2022; 14: 3151.

[9] Jha P, Gupta A, Baran TM, Maturen KE, Patel-Lippmann K, Zafar HM, et al. Diagnostic performance of the ovarian-adnexal reporting and data system (O-RADS) ultrasound risk score in women in the United States. JAMA Network Open. 2022; 5: e2216370.

[10] Liu Y, Cao L, Chen S, Zhou J. Diagnostic accuracy of ultrasound classifications—O-RADS US v2022, O-RADS US v2020, and IOTA SR—in distinguishing benign and malignant adnexal masses: enhanced by combining O-RADS US v2022 with tumor marker HE4. European Journal of Radiology. 2024; 181: 111824.

[11] Du Y, Xiao Y, Guo W, Yao J, Lan T, Li S, et al. Development and validation of an ultrasound-based deep learning radiomics nomogram for predicting the malignant risk of ovarian tumours. BioMedical Engineering OnLine. 2024; 23: 41.

[12] Ahmed H. The usefulness of the ultrasound diagnosis of suspicious ovarian masses based on the O-RADS classification system. Al-Azhar International Medical Journal. 2021; 2: 1–6.

[13] Ye L, Zhou G, Zhou L, Wang D, Xiong S, Liu C, et al. Diagnostic roles of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein, and cancer antigen 125 for ovarian cancer. Journal of International Medical Research. 2023; 51: 3000605231218557.

[14] Sastra WIG, Aditya PPK, Gradiyanto OE, Ketut S. Predictive value of preoperative inflammatory markers and serum CA 125 level for surgical outcome in Indonesian women with epithelial ovarian cancer. Cancer Biomarkers. 2022; 34: 123–129.

[15] Zhang W, Zhang Z, Qian L. Prognostic and clinicopathological significance of C-reactive protein in patients with ovarian cancer: a meta-analysis. World Journal of Surgical Oncology. 2024; 22: 8.

[16] Wang J, Zhu M, Zhou X, Wang T, Zhang J. Changes in tumor markers, coagulation function and serum VEGF in patients with ovarian cancer and benign ovarian disease. Journal of BUON. 2020; 25: 2287–2292.

[17] Chan JK, Tian C, Kesterson JP, Richardson MT, Lin K, Tewari KS, et al. The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: an NRG/GOG ancillary study. Gynecologic Oncology. 2022; 167: 429–435.

[18] Szulc-Kielbik I, Kielbik M, Nowak M, Klink M. The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer. 2021; 1876: 188639.